Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners


Laboratory Developed Test
ThyGeNEXT is a thyroid cancer mutational panel using next generation sequencing (NGS) simultaneously analyzes more than 150 genetic alterations associated with papillary and follicular thyroid carcinomas, the two most common forms of thyroid cancer. The ThyGeNEXT panel builds on the company’s ThyGenX panel (launched in August 2014) by adding numerous molecular markers, gene mutations, and RNA fusions, resulting in a more comprehensive set of indicators to identify malignant or benign nodules and ascertain aggressiveness and other characteristics.
Thyroid Gland Carcinoma, Thyroid Gland Papillary Carcinoma
ALK (Anaplastic lymphoma kinase), BRAF (B-raf proto-oncogene), GNAS (GNAS Complex Locus), HRAS (Harvey rat sarcoma viral oncogene homolog), KRAS (KRAS proto-oncogene GTPase), NRAS (Neuroblastoma RAS viral oncogene homolog)
See More ...
Next-Generation Sequencing (NGS)